araag2/HINT huggingface dataset:
Clinical trial NCT01503736 (phase 3, status: completed)
Conditions: hyperphosphatemia, end stage renal disease, esrd
ICD codes: N18.6, I12.0, I13.11, I13.2
Drugs: ferric citrate, ferric citrate, ferric citrate
SMILES: [Fe+3], [Fe+3], [Fe+3]
Eligibility criteria:

        Inclusion Criteria:

          -  Age>18 years and has a diagnosis of ESRD

          -  On a three-times per week hemodialysis regimen

          -  On a stable dose of a phosphate-binding agent for at least one month prior to study
             entry.

          -  If on vitamin D supplementation or calcitriol, must be on a stable dose for at least
             one month prior to study entry.

          -  Hct >= 20%

          -  Serum Ca level of 8 mg/dL to 10.5 mg/dL

        Exclusion Criteria:

          -  Is pregnant or lactating

          -  Clinically significant GI disorder

          -  Has tertiary hyperparathyroidism or is immediately post-operative from a
             parathyroidectomy (within the first 3 months post-op or the plasma Ca is <7 mg/dL)

          -  ferritin>800 ng/mL

          -  Unstable medical condition unsuitable for the study in the opinion of investigator

          -  Has been treated with an investigational agent within 30 days of enrollment

          -  Has a history of documented iron allergy or hemochromatosis
Clinical trial NCT00428090 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: rosiglitazone
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Clinical diagnosis of probable Alzheimer's Disease (AD).

          -  MMSE score 10 to 23

          -  Has not taken an approved AD therapy in last 30 days.

          -  No previous hypersensitivity/intolerance to AChEIs

          -  Have a regular caregiver.

        Exclusion criteria:

          -  Diagnosis of vascular dementia.

          -  Type I or secondary diabetes mellitus.

          -  Type II diabetes mellitus treated with insulin, sulfonylurea or glipizide.

          -  History or evidence of congestive heart failure, clinically significant peripheral
             edema or anemia.

          -  History of significant psychiatric illness, major depressive disorder or current
             depression needing initiation of treatment.
Clinical trial NCT00265824 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, bevacizumab, erlotinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        MAIN ELIGIBILITY CRITERIA

          -  Histologically proven metastatic adenocarcinoma of colon or rectum

          -  Documented inoperable disease (i.e., not suitable for complete carcinological surgical
             resection)

          -  Measurable lesion as assessed by CT scan or MRI in at least one dimension (longest
             diameter to be recorded) ≥ 20 mm with conventional CT scan or ≥ 10 mm with spiral CT
             scan

          -  No previous therapy for metastatic disease

          -  No history or evidence upon physical examination of CNS disease (e.g., non-irradiated
             CNS metastasis, seizure not controlled with standard medical therapy, or history of
             stroke) unless adequately treated

          -  No exclusive bone metastasis

          -  ECOG performance status 0-2

          -  WBC ≥ 1,500/mm^3

          -  Platelets ≥ 100,000/mm^3

          -  Hemoglobin > 9 g/dL (may be transfused to maintain or exceed this level)

          -  Proteinuria < 2+ by dipstick OR ≤ 1 g of protein on 24-hr urine collection

          -  Bilirubin < 1.5 times ULN

          -  Alkaline phosphatase < 3 times ULN

          -  No peripheral sensory neuropathy

          -  Negative pregnancy test

          -  Fertile patients must use effective means of contraception (oral contraceptives,
             intrauterine contraceptive device, barrier method of contraception in conjunction with
             spermicidal jelly, or surgically sterilization)

          -  No peripheral neuropathy ≥ grade 1

          -  No clinically significant (i.e. active) cardiovascular disease

          -  No evidence of bleeding diathesis or coagulopathy

          -  No serious, non-healing wound, ulcer, or bone fracture

          -  No significant ophthalmologic abnormality

          -  More than 28 days since prior major surgical procedure or open biopsy
Clinical trial NCT00699153 (phase 3, status: completed)
Conditions: ocular inflammation
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: loteprednol etabonate, vehicle of ophthalmic loteprednol etabonate
SMILES: [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects at least 18 years of age

          -  Subjects who have the ability to understand and sign an informed consent form and
             provide Health Insurance Portability and Accountability Act (HIPAA) authorization.

          -  Subjects who are candidate for routine, uncomplicated cataract surgery.

          -  Subjects who are not of childbearing potential or subjects who have a negative urine
             pregnancy test result at screening.

          -  Subjects must be willing and able to comply with all treatment and follow- up
             procedures.

        Exclusion Criteria:

          -  Subjects who have known hypersensitivity or contraindication to the study drug or its
             components.

          -  Subjects who have a history or presence of chronic generalized systemic disease that
             the investigator feels might increase the risk to the subject or compound the result
             of the study.

          -  Subjects who have a severe/serious ocular condition, or any other unstable medical
             condition that, in the Investigator's opinion, may preclude study treatment or
             follow-up.

          -  Subjects with elevated intraocular pressure (>/= 21 mm Hg), uncontrolled glaucoma, or
             being treated for glaucoma in the study eye.

          -  Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the
             non-study eye.

          -  Subjects who have had ocular surgery in the study eye within 3 months or in the fellow
             eye within 2 weeks prior to the screening visit.

          -  Women who are pregnant or breast feeding.

          -  Subjects who have participated in an investigational drug or device study within the
             last 30 days.

          -  Subjects previously randomized in this study.
Clinical trial NCT00088075 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  A responsible person must be available to accompany the subject to the site at each
             visit

          -  patient must meet the DSM-IV criteria for schizophrenia

        Exclusion Criteria:

          -  Patients with mild, moderate or severe mental retardation

          -  patients with a known or suspected history of substance dependence

          -  subjects weighing <35kg

          -  subjects who cannot swallow oral tablets
Clinical trial NCT00418379 (phase 3, status: completed)
Conditions: allergy
ICD codes: T78.40XS, T78.49XS, Z91.010, Z91.012, Z91.013, Z91.030, Z91.040
Drugs: 300 ir (4m), 300 ir (2m), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients aged 18 to 50 years

          -  Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen
             seasons

          -  Positive SPT and specific IgE values of at least Class 2 for grass pollen allergens

          -  A score of greater than or equal to 12 out of a possible 18 on the Retrospective
             Rhinoconjunctivitis Total Symptom Score (RRTSS)

        Exclusion Criteria:

          -  Patients with symptoms of rhinoconjunctivitis during the grass pollen season due to
             sensitisation to allergens other than grass pollen must not be included. Patients must
             be asymptomatic to all other allergens during the grass pollen season. Patients who
             have allergic rhinitis due to perennial allergen may not be included.

          -  Asthma requiring treatment other than beta-2 inhaled agonists.

          -  Patients who have received any desensitisation treatment for grass pollen or with any
             other allergen within the previous 5 years.
Clinical trial NCT01358864 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: bi 201335, pegylated interferon-alpha (ifn), ribavirin (rbv), placebo
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to
             screening

          2. Confirmed prior virological failure with an approved dose of PegIFN/RBV

          3. Age 18 to 70 years,

          4. HCV RNA (RiboNucleic Acid) = 1,000 IU/mL at screening,

        Exclusion criteria:

          1. HCV infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency
             Virus (HIV) co-infection

          2. Evidence of acute or chronic liver disease due to causes other than chronic HCV
             infection,

          3. Decompensated liver disease, or history of decompensated liver disease,

          4. Body weight < 40 or > 125 kg,

          5. Clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary
             disease, history or evidence of retinopathy or clinically significant ophthalmological
             disorder

          6. Pre-existing psychiatric condition that could interfere with the subject's
             participation in and completion of the study

          7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or G6PD
             deficit)

          8. Hemoglobin < 12 g/dL for women and < 13 g/dL for men

          9. Patients who have been previously treated with at least one dose of any antiviral or
             immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV
             infection including and not restricted to protease or polymerase inhibitors,
Clinical trial NCT00573443 (phase 3, status: completed)
Conditions: pseudobulbar affect (pba)
ICD codes: F48.2
Drugs: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, placebo
SMILES: [H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1, [H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  The patient has a diagnosis of Amyotrophic Lateral Sclerosis (according to El Escorial
             Criteria, WFN, 1998) and the time from diagnosis of ALS is not be longer than 30
             months, or the patient has a diagnosis of multiple sclerosis or probable multiple
             sclerosis (according to McDonald criteria, 2001)

          -  The patient has a clinical history and clinical relevant symptoms of Pseudobulbar
             Affect (PBA)

          -  CNS-LS score at baseline is 13 or greater

        Main Exclusion Criteria:

          -  Patients with myasthenia gravis

          -  Any personal history of complete heart block, QTc prolongation, or torsades de pointes

          -  Any family history of congenital QT interval prolongation syndrome

          -  Patients with known sensitivity to quinidine, dextromethorphan or opiate drugs
             (codeine, etc.)
Clinical trial NCT00069121 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin, leucovorin (lv), 5-fluorouracil (5-fu)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed colon carcinoma, AJCC/UICC Stage III (Dukes stage C)

          -  Complete tumor resection; Patients operated with curative intent and with no
             macroscopic or microscopic evidence for remaining tumor who can be randomized to
             either treatment arm within 8 weeks after surgery. As this is an adjuvant trial
             patients should never have had any evidence of metastatic disease (including presence
             of tumor cells in the ascites).

          -  Have a life expectancy of at least 5 years

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Sexually active males and females (of childbearing potential) unwilling to practice
             contraception during the study

          -  Previous cytotoxic chemotherapy, radiotherapy or immunotherapy, for the currently
             treated colon cancer

          -  Patients who have not completely recovered from surgery
Clinical trial NCT00313313 (phase 3, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: saxagliptin, saxagliptin, glyburide, placebo, glyburide, metformin
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes.

          -  Treated with a sulfonylurea for at least 2 months.

          -  Inadequate blood sugar control.

          -  Are not on any other medications to lower blood sugar.

          -  No major heart, liver or kidney problems.

          -  Women not pregnant or breast feeding.
Clinical trial NCT01290679 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: placebo, tmc435, peginterferon alpha-2a or peginterferon alpha-2b (pegifnα-2a/b), ribavirin (rbv)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Genotype 1 hepatitis C infection (confirmed at screening)

          -  Participant has not received any prior treatment for hepatitis C

          -  Participant must have had a liver biopsy within 3 years before screening (or between
             the screening and baseline visit) showing chronic hepatitis C infection

          -  Must agree to use 2 forms of effective contraception throughout study (both males and
             females)

        Exclusion Criteria:

          -  Infection with HIV or non genotype 1 hepatitis C

          -  Liver disease not related to hepatitic C infection

          -  Hepatic decompensation

          -  Significant laboratory abnormalities or other active diseases

          -  Pregnant or planning to become pregnant
Clinical trial NCT00574873 (phase 3, status: completed)
Conditions: chronic myeloid leukemia
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: bosutinib, imatinib
SMILES: COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Cytogenetic diagnosis of chronic phase Ph+ CML diagnosed less than 6 months.

          -  Diagnosis of CML chronic phase confirmed.

          -  Adequate hepatic and renal function.

          -  Able to take oral tablets.

        Exclusion Criteria:

          -  Exclusions include Philadelphia negative CML.

          -  Prior anti-leukemia treatment.

          -  Prior stem cell transplant.
Clinical trial NCT00231153 (phase 3, status: completed)
Conditions: infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: omiganan 1% gel, povidone-iodine 10%
SMILES: [H]N=C(N([H])[H])N([H])CCC[C@H](N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC(C)C)N([H])C(=O)[C@@H](N([H])[H])[C@@H](C)CC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])[H], CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  New insertion of at least 1 noncuffed (nontunneled) temporary central venous catheter

          -  Males and females of at least 13 years of age

          -  A negative urine or serum pregnancy test at baseline

        Exclusion Criteria:

          -  Insertion of, or requirement for, any study catheter impregnated/bonded with an
             antimicrobial substance

          -  High probability of death within 14 days of enrollment as assessed by the investigator

          -  Prior treatment with vancomycin (intravenous administration only), daptomycin,
             linezolid, or quinupristin/dalfopristin, within 48 hours of first study catheter
             insertion or prior treatment with tigecycline within one week of first study catheter
             insertion

          -  Requirement for topical antibiotic use within 10 cm of any study catheterization site

          -  Known severe neutropenia (absolute neutrophil count [ANC] < 500 mm3) or recent
             administration of antineoplastic therapy expected to result in severe neutropenia
             within 48 hours of first study catheter insertion

          -  Routine non-complicated coronary artery bypass grafting (CABG) patients, bone marrow
             transplant (BMT) or solid organ transplant (SOT) patients

          -  Patients anticipated to be catheterized for less than 48 hours

          -  Patients who have a suspected or known bloodstream infection at enrollment

          -  Burn patients or patients with toxic epidermal necrolysis

          -  Known allergy to adhesive tape or adhesive bandages
Clinical trial NCT00402363 (phase 3, status: completed)
Conditions: fibrillation, atrial
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: omega-3-acid ethyl esters, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women age 18 years or older

          -  History of symptomatic atrial fibrillation (either paroxysmal or persistent)

          -  Provide written informed consent and authorization for protected health information
             disclosure

        Exclusion Criteria:

          -  Permanent (chronic) atrial fibrillation

          -  Antiarrhythmic drug therapy which cannot be stopped

          -  Use of amiodarone with prior 6 months

          -  History of unsuccessful cardioversion

          -  History of certain cardiovascular conditions or cardiac surgery within prior 6 months

          -  History of stroke within prior 6 months

          -  Implanted cardio-defibrillator

          -  Certain circulatory, thyroid, pulmonary, liver, kidney, musculoskeletal or metabolic
             conditions, or cancer (except non-melanoma skin cancer)

          -  Poorly controlled diabetes
Clinical trial NCT01241240 (phase 3, status: completed)
Conditions: glaucoma, open-angle, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (triple combination therapy), fixed combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Ocular hypertension or primary open-angle glaucoma in each eye

          -  Requires treatment with IOP-lowering medication in both eyes

        Exclusion Criteria:

          -  Required chronic use of ocular medications during the study other than study
             medication

          -  Use of any corticosteroids within 30 days

          -  History of any prior eye surgery, except for uncomplicated eye surgery performed more
             than 6 months before the Screening visit

          -  Anticipated wearing of contact lenses during the study
Clinical trial NCT01292837 (phase 3, status: completed)
Conditions: epilepsy, generalized tonic-clonic seizures
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, A21.7, I70.91, R60.1, R61, F40.11, F41.1, K65.0
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  An epileptic patient with generalized tonic-clonic seizures that are classifiable
             according to the International League Against Epilepsy classification of epileptic
             seizures (Epilepsia, 1981)

          -  A patient on a stable dose of 1 or 2 anti-epileptic drugs for the last 4 weeks
             (potassium bromide and sodium bromide for the last 12 weeks) prior to the Combined
             Baseline Period and during the Combined Baseline Period

        Exclusion Criteria:

          -  Presence of any sign (clinical or imaging procedures) suggesting a progressive brain
             lesion/disease, in particular, progressive disorder with epileptic seizures

          -  Diagnosis of Lennox-Gastaut Syndrome

          -  Confirmed focal epilepsy based on clinical signs (seizure types), with consistent
             electroencephalogram and magnetic resonance imaging features

          -  A history of convulsive or nonconvulsive status epilepticus while taking concomitant
             anti-epileptic drugs for the last 3 months prior to Visit 1